Manara - Qatar Research Repository
Browse
efficacy_of_sodium_glucose_co_transporter_2.25.pdf (190.79 kB)

Efficacy of sodium-glucose co-transporter 2 inhibitors in patients with type II diabetes

Download (190.79 kB)
journal contribution
submitted on 2024-03-13, 08:33 and posted on 2024-03-13, 08:35 authored by Mohammed Ibn-Mas’ud Danjuma, Shaikha Al Shokri, Arwa Ibrahim YA Al Saud, Mohamed Nabil Abdelsalam Elshafei, Haajra Fatima, Suhail Doi, Mubarak Ariyo Bidmos

Background:

Recent systematic reviews have evaluated the efficacy of sodium-glucose co-transporter 2 inhibitors (SGLT2) inhibitors (SGLT2I) in improving glycaemic control and mortality in patients with type II diabetes mellitus. None have incorporated the most recent study or utilized the generalized pairwise modeling methodology network meta-analysis (NMA), as well as a novel bias risk assessment approach.

Methods:

We propose to conduct literature search of all randomized controlled clinical trials published in English language evaluating the efficacy of (SGLT2I) versus placebo or usual standard of care from the inception of following databases to September 30, 2019: Controlled Clinical Trials Cochrane Controlled Trials Register (CCTR), Cochrane Database of Systematic Reviews (CDSR), EMBASE, Database of Abstracts of Reviews of Effectiveness (DARE), PubMed. Two reviewers will independently search these databases to identify studies that satisfy pre-specified eligibility criteria. Study bias risk assessment amongst other methodology quality evaluation of the studies will be carried out using a novel risk bias assessment tool.

Results:

We anticipate that the result of this review will provide additional insight into the ranking of the efficacy of various (SGLT2I) in type II diabetic patients especially as it relates to mortality, glycemic control, and body weight reduction.

Conclusion:

The result of this review will be useful informing therapeutic decisions by policy makers with regards to commissioning of diabetic care.

Prospero registration number: CRD42019139708

Other Information

Published in: Medicine
License: http://creativecommons.org/licenses/by/4.0
See article on publisher's website: https://dx.doi.org/10.1097/md.0000000000018198

Funding

Open Access funding provided by the Qatar National Library.

History

Language

  • English

Publisher

Wolters Kluwer

Publication Year

  • 2019

License statement

This Item is licensed under the Creative Commons Attribution 4.0 International License.

Institution affiliated with

  • Hamad Medical Corporation
  • Hamad General Hospital - HMC
  • Weill Cornell Medicine - Qatar
  • Qatar University
  • Qatar University Health - QU

Methodology

We propose to conduct literature search of all randomized controlled clinical trials published in English language evaluating the efficacy of (SGLT2I) versus placebo or usual standard of care from the inception of following databases to September 30, 2019: Controlled Clinical Trials Cochrane Controlled Trials Register (CCTR), Cochrane Database of Systematic Reviews (CDSR), EMBASE, Database of Abstracts of Reviews of Effectiveness (DARE), PubMed. Two reviewers will independently search these databases to identify studies that satisfy pre-specified eligibility criteria. Study bias risk assessment amongst other methodology quality evaluation of the studies will be carried out using a novel risk bias assessment tool.

Usage metrics

    Hamad Medical Corporation

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC